SNIPR Advances SNIPR001 Into Phase 2 for E. coli Prevention
COPENHAGEN, Denmark — September 17, 2026 SNIPR announced that the first patient has been enrolled in Part 2 of...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
COPENHAGEN, Denmark — September 17, 2026 SNIPR announced that the first patient has been enrolled in Part 2 of...
Cambridge, Massachusetts, USA, August 8, 2026 Biogen has completed the acquisition of RayThera Inc., a privately held biotechnology company...
San Diego, California, USA, August 8, 2026 Blacksmith Medicines has announced the publication of new research in the Journal...
